Gilead going strong at 20

06/23/2007 | San Francisco Chronicle

On Gilead Sciences' 20th anniversary, analysts said the Bay Area biotech is in a strong position to remain independent and expand into new treatment areas. Gilead, the nation's dominant seller of HIV drugs, had sales of $3 billion in 2006, and some analysts are predicting substantial growth in revenue this year.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA